All News

portfolio-news

GlycoEra Appoints Andrea Matthews as Chief Business Officer to Support Next Phase of Company Growth

Posted September 22, 2026

portfolio-news

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

Posted September 9, 2026

ventures-news

Etienne Cousin joins LifeArc Ventures

Posted July 27, 2026

ventures-news

Congratulations to our portfolio company RQ Biotechnology Ltd which has announced the completion of an oversubscribed $115 million (£85.5 million) Series A financing.

Posted June 24, 2026

portfolio-news

RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention

Posted June 24, 2026

portfolio-news

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Posted June 22, 2026

portfolio-news

Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director

Posted June 12, 2026

portfolio-news

AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

Posted May 14, 2026

portfolio-news

Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board

Posted May 14, 2026

ventures-news

Jonathan Nash, MD, Investment Principal at LifeArc Ventures, congratulates portfolio company, Cytospire, on their £61 million Series A fundraise

Posted May 5, 2026

portfolio-news

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Posted May 5, 2026

portfolio-news

AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid

Posted May 4, 2026